Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MOTIF BIO PLC. We currently have 60 research reports from 6 professional analysts.
|08Feb17 07:00||RNS||Director/PDMR Shareholding|
|07Feb17 07:02||RNS||Director/PDMR Shareholding|
|31Jan17 07:00||RNS||Clinical trial finishes patient treatment phase|
|27Jan17 18:13||RNS||Holding(s) in Company|
|18Jan17 07:05||RNS||Director/PDMR Shareholding|
|18Jan17 07:00||RNS||Appointment of Chief Financial Officer|
|09Jan17 17:28||RNS||Issue of Equity|
Frequency of research reports
Research reports on
MOTIF BIO PLC
MOTIF BIO PLC
01 Feb 17
"The FOMC’s Monetary Policy Statement, which is due at 19:00hrs GMT, will likely be today’s principal talking point. Not that any change in the discount rate is anticipated, but traders will be listening acutely for any suggestion as to when the first of 2017’s three anticipated hikes might kick-off. This will be particularly sensitive for the US$, which yesterday slid to its lowest level against the international basket since Trump’s election was seen to drive the currency to a 14-year high in November. While there may be some truth in the idea that month-end rebalancing by forex traders somewhat weighed on the Dollar, suggestions from President Trump that Japan and China are devaluing their currencies to boost international trade, while a US trade advisor tells the FT that Germany benefits from a ‘grossly undervalued’ Euro, hints that there are some early signs of panic in the White House. Yet the reality of Trump’s rallying call ‘America First’ is founded on inward looking, reflationary and protectionist policies, which are destined primarily to power the US$ ever upward, and something that even Donald might find he can do very little to stop. The damage inflicted on the Mexican Peso after its government drew swords with the President was a clear warning to all US trading partners, but most particularly China, of troubles ahead. Reflecting on this, the Dow Jones remained yesterday’s main casualty, with the other principal US indices closing with just fractional movements. Catching up following the Lunar New Year break, the Hang Seng fell quite sharply, reflecting also news that China’s Manufacturing PMI fell for the second straight month in January. Elsewhere in Asia, the Nikkei recovered from an early setback to close slightly in the positive, while the ASX gained as commodity plays and financials marginally firmed. Other than the Nationwide Housing Prices index, there is little UK macro data due today, although January Markit Manufacturing PMI figures cover most EU territories, including Great Britain. At 10:00hrs GMT, the European commission is also due to release its Economic Growth Forecasts, while later a large batch of US statistics, including ISM Manufacturing, Construction Spending and Vehicle Sales for January, precede this evening’s Fed decision. UK corporates due to release earnings or trading updates include AG Barr (BAG.L), Low & Bonar (LWB.L) and TalkTalk (TALK.L). With the US$ now trading off yesterday’s lows, London equities are expected to recoup some of yesterday’s losses, with the FTSE-100 seen rising some 30 points during opening business. Investors will also be keeping a weary eye out for reports from the Commons this morning, with as many as 100 MPs reportedly planning to vote against a law to trigger Article 50. " - Barry Gibb, Research Analyst
Patient treatment completed in REVIVE-1
31 Jan 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), a late clinical stage antibiotic development company, has announced that the treatment phase has finished for the last patient in REVIVE-1, the first of two phase III clinical trials of iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI). With this news Motif Bio is firmly on-track to report headline results from the trial in Q2. We believe iclaprim remains a highly valuable new antibiotic and take the rapid enrolment of patients in this trial as an indicator of the strong clinical need for a product with its performance characteristics, particularly for patients with renal impairment (some 26% of the estimated 3.6m hospitalized ABSSSI patients in the USA annually). Our fair value estimate for Motif Bio stands at 107p.
Further de-risking of iclaprim
31 Jan 17
Motif is a clinical stage development company focused on a best-in-class drug that targets bacteria resistant to most other commonly used antibiotics. The FDA has agreed a plan of two carefully constructed Phase III trials that will allow approval of iclaprim, opening it up to a $3.0bn market segment. The company has just achieved an important milestone with the last patient completing treatment in the REVIVE-1 trial, which keeps in on its revised (earlier) schedule to release headline data in 2Q 2017. Following a recent NASDAQ IPO and EU Placing, the company has sufficient capital to complete the first trial (REVIVE-1).
Update post NASDAQ IPO
20 Jan 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company is now funded to completion of REVIVE-1, the first of its two phase III clinical trials of its lead drug candidate, iclaprim. This antibiotic is being developed for the treatment of serious and life threatening bacterial infections, particularly those caused by drug resistant bacteria. It is a next-generation antibiotic targeting an under-utilised mechanism of action which causes rapid killing of bacteria making it an attractive candidate for acute infections. Given our belief in iclaprim showing positive results in REVIVE-1 and Motif’s current share price, we think an investment now would be timely with REVIVE-1 on-track to report soon (Q2’17). Our risk-adjusted fair value estimate for Motif Bio now stands at £210m (107p per share).
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017